

## Chapter 5

# METABOLIC REPROGRAMMING AND MITOCHONDRIAL ACTIVITY IN CANCER CELLS

Aynur KARADAĞ GÜREL<sup>1</sup>

### Introduction

Cancer is characterised by uncontrolled cell growth. Metabolic demands to sustain fast proliferation should be compelling since aerobic metastasis is that the initial and most ordinarily shared characteristic of cancer. throughout the last decade, the importance of metabolic reprogramming has been at the middle of attention. However, despite all the information gained on cancer biology, the sphere isn't able to reach agreement on the problem of mitochondria: Are broken mitochondria the cause for aerobic metastasis in cancer? Warburg projected the broken mitochondria theory over eighty years ago, the sphere has been testing the speculation equally long (Gaude, 2018, Zhu et al., 2018).

An important advantage of eukaryotic cell evolution is an energy source for cell metabolism, which leads to an energy gain. Beyond bioenergetics, mitochondrial biology has important functions in mitochondrial biogenesis, fission and fusion dynamics, cell death susceptibility, oxidative stress regulation, metabolism and signaling pathways. In cancer, the cells rearrange their metabolism to save energy and affect mitochondrial function by converting from oxidative phosphorylation to aerobic glycolysis (Gaude, 2018, Pustynnikov et al., 2018). More cancer cells also can modulate energy metabolism inside the cancer microenvironment as well as immune cells and induce “metabolic energy” of anticancer immune response.

The classical approaches to cancer cell mitochondria generally aim to either induce altered energy metabolism or directly affect the functions of mitochondrial antiapoptotic proteins, but many of these approaches have specific properties and carry side effects. Various types of cancer contain somatic mitochondrial DNA (mtDNA) mutations and a specific immune response to mutated mitochondrial proteins has been observed. An attractive alternative way of targeting mitochondria in cancer cells is the induction of an adaptive immune response against mutated mitochondrial proteins (Zhu et al., 2018, Pustynnikov et al., 2018).

---

<sup>1</sup>Assist. Prof., Usak University, Faculty of Medicine, Department of Medical Biology, aynur.karadag@usak.edu.tr

The explanation of the complex structure of the tumor and its microenvironment will help explain the behaviors of cancer cells. The change in the way energy needs are met along with the changing microenvironment clearly reveals that the mechanisms by which cancer cells are influenced should be clarified. Based on this information, although cancer cells have dysfunctional mitochondria, they prefer to use oxidative phosphorylation instead of glycolysis, indicating that they have functional mitochondria. And that the source of these mitochondria are healthy mitochondria that migrate from neighboring cells forming the microenvironment.

Identifying the molecular mechanisms involved in carcinogenesis is an important way to develop new strategies in cancer prevention and treatment. Metabolic reprogramming of cancer cells is seen as a promising approach and mitochondrial activity is considered as a target for cancer therapy in particular.

## References

- Archer, S.L. (2013). "Mitochondrial dynamics- mitochondrial fission and fusion in human diseases", *New Eng J Med*, 369,2236-51.
- Bai, R.K., Wong, L.J. (2005). "Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease", *J Mol Diagn*, 7, 613-622.
- Boland, M.L., Chourasia, A.H., Macleod, K.F. (2013). "Mitochondrial dysfunction in cancer", *Front Oncol*, 3,1-18.
- Bonuccelli, G., Tsigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G., Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P. (2010). "Ketones and lactate 'fuel' tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism", *Cell Cycle*, 9(17),3506-3514.
- Brandon, M., Baldi, P. and Wallace, D.C. (2006). "Mitochondrial mutations in cancer", *Oncogene*, 25, 4647-62.
- Cairns, R.A, Harris, I.S, Mak, T.W. (2011). "Regulation of cancer cell metabolism", *Nat Rev Cancer*, 11,85-95.
- Cantor, J.R., Sabatini, D.M. (2012). "Cancer cell metabolism: One hallmark, many faces", *Cancer Discov*, 2, 881-898.
- Chen, X., Li, J., Hou, J., Xie, Z. and Yang, F. (2010). "Mammalian mitochondrial proteomics: insights into mitochondrial functions and mitochondria-related diseases", *Expert Rev Proteomics*, 7, 333-45.
- Da silva, A.F, Mariotti, F.R., Maximo, V., Campello, S. (2014). "Mitochondria dynamism: of shape, transport and cell migration", *Cell Mol Life Sci*,71,2313-24.
- Desouki, M.M., Kulawiec, M., Bansal, S., Das, G.M. and Singh, K.K. (2005). "Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors", *Cancer Biol Ther*, 4, 1367-73.
- Eng, C., Kiuru, M., Fernandez, M.J. and Aaltonen, L.A. (2003). "A role for mitochondrial enzymes in inherited neoplasia and beyond", *Nat.Rev Cancer*, 3, 193-202.
- Hanahan, D., Weinberg, R.A. (2011). "The hallmarks of cancer: The next Generation", *Cell*, 145, 646-674.
- Huuskes, B.M., Wise, A.F, Cox, A.J., Lim, E.X., Payne, N.L., Kelly, D.J., Samuel, C.S., Ricardo, S.D. (2014). "Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy", *FASEB J*, 29(2),540-53.
- Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N, Yamaguchi, A, Imanishi, H, Nakada, K, Honma, Y, Hayashi, J. (2008). "ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis", *Science*, 320, 661-4.
- Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., Hayashi, J. (2008). "ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis", *Science*, 320, 661-4.
- Karbowski, M. (2010). "Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis", *Adv Exp Med Biol*, 687, 131-42.

Ko, Y.H., Lin, Z., Flomenberg, N., Pestell, R.G., Howell, I.A., Sotgia, F., Lisanti, M.P., Martinez-Outschoorn, U.E. (2011). "Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance", *Cancer Biol Ther*, 12(12),1085-97.

Lunt, S.Y., Vander Heiden, M.G. (2011). "Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation", *Annu Rev Cell Dev Biol*, 27, 441-464.

Ma, Y., Bai, R.K., Trieu, R., Wong, L.J. (2010). "Mitochondrial dysfunction in human breast cancer cells and their trans-mitochondrial hybrids", *Biochim Biophys Acta*, 1797(1),29-37.

Martinez-Outschoorn, U.E., Goldberg, A., Lin, Z., Ko, Y.H., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R.G., Howell, A., Sotgia, F., Lisanti, M.P. (2011). "Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells", *Cancer Biol Ther*, 12, 924-38.

Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P. (2012). "Power surge: supporting cells "fuel" cancer cell mitochondria", *Cell Metab*, 15(1), 4-5.

Nieman, K.M., Romero, I.L., Van Houten, B., Lengyel, E. (2013). "Adipose tissue and adipocytes support tumorigenesis and metastasis", *Biochim Biophys Acta*, 1831(10),1533-41.

Ono, M., Ohkouchi, S., Kanehira, M., Tode, N., Kobayashi, M., Ebina, M., Nukiwa, T., Irokawa, T., Ogawa, H., Akaike, T., Okada, Y., Kurosawa, H., Kikuchi, T., Ichinose, M. (2014). "Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1", *Mol Ther*, 23(3),549-60.

Ortiz, L.A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, N., Phinney, D.G. (2003). "Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects", *Proc Nat Acad Sci U S A*, 100(14),8407-11.

Rodríguez-Enríquez, S., Torres-Márquez, M.E., Moreno-Sánchez, R. (2000). "Substrate oxidation and ATP supply in AS-30D hepatoma cells", *Arch Biochem Biophys*, 375(1),21-30.

Sotgia, F., Whitaker-Menezes, D., Martinez-Outschoorn, U.E., Salem, A.F., Tsirigou, A., Lamb, R., Sneddon, S., Hult, J., Howell, A., Lisanti, M.P. (2012). "Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells", *Cell Cycle*, 11(23),4390-401.

Tan, A.S., Baty, J.W., Dong, L.F., Bezawork-Geleta, A., Endaya, B., Goodwin, J., Bajzikova, M., Kovarova, J., Peterka, M., Yan, B., Pesdar, E.A., Sobol, M., Filimonenko, A., Stuart, S., Vondrusova, M., Kluckova, K., Sachaphibulkij, K., Rohlena, J., Hozak, P., Truksa, J., Eccles, D., Haupt, L.M., Griffiths, L.R., Neuzil, J., Berridge, M.V. (2015). "Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA", *Cell Metab*, 21, 81-94.

Tan, D.J., Bai, R.K., Wong, L.J. (2002). "Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer", *Cancer Res*, 62,972-976.

Vander Heiden, M.G., Cantley, L.C., Thompson, C.B. (2009). "Understanding the Warburg effect: the metabolic requirements of cell proliferation", *Science*, 324,1029-1033.

Vander Heiden, M.G., Lunt, S.Y., Dayton, T.L., Fiske, B.P., Israelsen, W.J., Mattaini, K.R., Vokes, N.I., Stephanopoulos, G., Cantley, L.C., Metallo, C.M., Locasale, J.W. (2011). "Metabolic pathway alterations that support cell proliferation", *Cold Spring Harb Symp Quant Biol*, 76, 325-334.

Willem, H.K., Patricia, L.B., Chi, V.D. (2011). "Otto Warburg's contributions to current concepts of cancer metabolism", *Nat Rev Cancer*, 11, 325-337.

Gaude, E. (2018). Mitochondrial metabolism in cancer transformation and progression (Doctoral thesis). <https://doi.org/10.17863/CAM.22270>.

Pustynnikov S, Costabile F, Beghi S, Faccibene A. (2018) Targeting mitochondria in cancer: current concepts and immunotherapy approaches. *Transl Res*. Jul 31. pii: S1931-5244(18)30114-2.

Boyle KA, Van Wickle J, Hill RB, Marchese A, Kalyanaraman B, Dwinell MB. (2018). Mitochondria-targeted drugs stimulate mitophagy and abrogate colon cancer cell proliferation. *J Biol Chem*. Aug 7. pii: jbc.RA117.001469.

Zhu Y, Dean AE, Horikoshi N, Heer C, Spitz DR, Gius D. (2018) Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy. *J Clin Invest*. Aug 31,128(9):3682-3691.

Chakrabarty S, Kabekkodu SP, Singh RP, Thangaraj K, Singh KK, Satyamoorthy K. (2018) Mitochondria in health and disease. *Mitochondrion*. Jun 23. pii: S1567-7249(18)30144-2.